-$0.64 Earnings Per Share Expected for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) This Quarter

Equities research analysts expect Iovance Biotherapeutics, Inc. (NASDAQ:IOVAGet Rating) to post earnings per share of ($0.64) for the current quarter, Zacks reports. Zero analysts have made estimates for Iovance Biotherapeutics’ earnings. The lowest EPS estimate is ($0.73) and the highest is ($0.59). Iovance Biotherapeutics reported earnings per share of ($0.51) in the same quarter last year, which suggests a negative year-over-year growth rate of 25.5%. The company is expected to announce its next quarterly earnings report after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Iovance Biotherapeutics will report full-year earnings of ($2.64) per share for the current year, with EPS estimates ranging from ($3.20) to ($2.23). For the next year, analysts forecast that the business will report earnings of ($2.35) per share, with EPS estimates ranging from ($2.81) to ($1.92). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Iovance Biotherapeutics.

Iovance Biotherapeutics (NASDAQ:IOVAGet Rating) last issued its quarterly earnings results on Thursday, February 24th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.07). During the same quarter in the prior year, the firm earned ($0.47) EPS.

A number of brokerages recently issued reports on IOVA. Chardan Capital lowered their price target on shares of Iovance Biotherapeutics from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Friday, February 25th. Truist Financial lowered their price target on shares of Iovance Biotherapeutics from $32.00 to $29.00 in a research report on Thursday, April 7th. Wells Fargo & Company lowered their price target on shares of Iovance Biotherapeutics from $35.00 to $25.00 in a research report on Wednesday, January 5th. Robert W. Baird lifted their target price on shares of Iovance Biotherapeutics from $30.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, April 7th. Finally, StockNews.com initiated coverage on shares of Iovance Biotherapeutics in a report on Thursday, March 31st. They issued a “sell” rating for the company. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $31.83.

Hedge funds have recently made changes to their positions in the company. UBS Group AG grew its stake in shares of Iovance Biotherapeutics by 213.8% in the third quarter. UBS Group AG now owns 196,284 shares of the biotechnology company’s stock worth $4,840,000 after acquiring an additional 133,742 shares during the period. Principal Financial Group Inc. grew its stake in shares of Iovance Biotherapeutics by 4.1% in the third quarter. Principal Financial Group Inc. now owns 546,867 shares of the biotechnology company’s stock worth $13,486,000 after acquiring an additional 21,784 shares during the period. Banque Pictet & Cie SA grew its stake in shares of Iovance Biotherapeutics by 701.0% in the fourth quarter. Banque Pictet & Cie SA now owns 534,036 shares of the biotechnology company’s stock worth $10,195,000 after acquiring an additional 467,364 shares during the period. Senator Investment Group LP bought a new stake in shares of Iovance Biotherapeutics in the third quarter worth approximately $12,330,000. Finally, Boxer Capital LLC bought a new stake in shares of Iovance Biotherapeutics in the third quarter worth approximately $27,126,000. Hedge funds and other institutional investors own 94.37% of the company’s stock.

Shares of NASDAQ IOVA opened at $15.15 on Thursday. Iovance Biotherapeutics has a 1 year low of $12.18 and a 1 year high of $32.15. The stock has a market cap of $2.38 billion, a P/E ratio of -6.82 and a beta of 0.83. The firm has a 50-day moving average of $15.72 and a 200 day moving average of $17.94.

Iovance Biotherapeutics Company Profile (Get Rating)

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.

Featured Articles

Get a free copy of the Zacks research report on Iovance Biotherapeutics (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.